PURPOSE: To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system. PATIENTS AND METHODS: Patients had histologically proven, unidimensionally measurable malignant melanoma, incurable by standard therapy. Prior adjuvant immunotherapy was allowed, but patients were otherwise untreated for advanced disease. Flavopiridol was administered at a dose of 50 mg/m(2) IV over 1 hour daily x 3 days every 3 weeks. Patients were assessed for response every 2 cycles. RESULTS: 17 patients were accrued over 5 months. No objective responses were documented in the 16 patients evaluable for response. Seven patients (44%) had stable disease after 2 cycles, with a median of 2.8 months (range 1.8-9.2). The most common treatment-related non-hematologic toxicities were diarrhea (82%), nausea (47%), fatigue (41%), anorexia (35%) and vomiting (29%). Most treatment-related toxicities were mild, except for diarrhea (grade 3 in 3 patients, grade 4 in 1 patient), nausea (grade 3 in 1 patient) and tumor pain (grade 3 in 1 patient). Hematologic toxicities were minimal, none worse than grade 2. Eighty-eight percent of patients received >/=90% planned dose intensity; 2 patients had dose reductions for gastrointestinal (GI) toxicity. CONCLUSIONS: Flavopiridol is well tolerated at the dose regimen used in this study, with an acceptable (primarily GI) toxicity profile. Although 7 of the 16 patients had stable disease ranging from 1.8 to 9.2 months in duration, there was no evidence of significant clinical activity in malignant melanoma by objective response criteria.
PURPOSE: To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system. PATIENTS AND METHODS: Patients had histologically proven, unidimensionally measurable malignant melanoma, incurable by standard therapy. Prior adjuvant immunotherapy was allowed, but patients were otherwise untreated for advanced disease. Flavopiridol was administered at a dose of 50 mg/m(2) IV over 1 hour daily x 3 days every 3 weeks. Patients were assessed for response every 2 cycles. RESULTS: 17 patients were accrued over 5 months. No objective responses were documented in the 16 patients evaluable for response. Seven patients (44%) had stable disease after 2 cycles, with a median of 2.8 months (range 1.8-9.2). The most common treatment-related non-hematologic toxicities were diarrhea (82%), nausea (47%), fatigue (41%), anorexia (35%) and vomiting (29%). Most treatment-related toxicities were mild, except for diarrhea (grade 3 in 3 patients, grade 4 in 1 patient), nausea (grade 3 in 1 patient) and tumor pain (grade 3 in 1 patient). Hematologic toxicities were minimal, none worse than grade 2. Eighty-eight percent of patients received >/=90% planned dose intensity; 2 patients had dose reductions for gastrointestinal (GI) toxicity. CONCLUSIONS:Flavopiridol is well tolerated at the dose regimen used in this study, with an acceptable (primarily GI) toxicity profile. Although 7 of the 16 patients had stable disease ranging from 1.8 to 9.2 months in duration, there was no evidence of significant clinical activity in malignant melanoma by objective response criteria.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: A M Senderowicz; D Headlee; S F Stinson; R M Lush; N Kalil; L Villalba; K Hill; S M Steinberg; W D Figg; A Tompkins; S G Arbuck; E A Sausville Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: R W Robey; W Y Medina-Pérez; K Nishiyama; T Lahusen; K Miyake; T Litman; A M Senderowicz; D D Ross; S E Bates Journal: Clin Cancer Res Date: 2001-01 Impact factor: 12.531
Authors: G K Schwartz; D Ilson; L Saltz; E O'Reilly; W Tong; P Maslak; J Werner; P Perkins; M Stoltz; D Kelsen Journal: J Clin Oncol Date: 2001-04-01 Impact factor: 44.544
Authors: V Patel; A M Senderowicz; D Pinto; T Igishi; M Raffeld; L Quintanilla-Martinez; J F Ensley; E A Sausville; J S Gutkind Journal: J Clin Invest Date: 1998-11-01 Impact factor: 14.808
Authors: Antoinette R Tan; Donna Headlee; Richard Messmann; Edward A Sausville; Susan G Arbuck; Anthony J Murgo; Giovanni Melillo; Suoping Zhai; William D Figg; Sandra M Swain; Adrian M Senderowicz Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: Jessica L F Teh; Timothy J Purwin; Evan J Greenawalt; Inna Chervoneva; Allison Goldberg; Michael A Davies; Andrew E Aplin Journal: Cancer Res Date: 2016-08-03 Impact factor: 12.701
Authors: Matthew A Held; Casey G Langdon; James T Platt; Tisheeka Graham-Steed; Zongzhi Liu; Ashok Chakraborty; Antonella Bacchiocchi; Andrew Koo; Jonathan W Haskins; Marcus W Bosenberg; David F Stern Journal: Cancer Discov Date: 2012-12-13 Impact factor: 39.397
Authors: Mylinh T Duong; Said Akli; Sira Macalou; Anna Biernacka; Bisrat G Debeb; Min Yi; Kelly K Hunt; Khandan Keyomarsi Journal: Cancer Res Date: 2013-08-16 Impact factor: 12.701
Authors: Antonio Jimeno; Jing Li; Wells A Messersmith; Daniel Laheru; Michelle A Rudek; Manoj Maniar; Manuel Hidalgo; Sharyn D Baker; Ross C Donehower Journal: J Clin Oncol Date: 2008-10-27 Impact factor: 44.544